FDA Circulatory System Devices Panel
This article was originally published in The Gray Sheet
Executive Summary
Convening Dec. 5 at the Holiday Inn in Gaithersburg, Maryland to review premarket approval applications for Medtronic's Atakr radiofrequency ablation system and Thoratec Laboratories' Thoratec ventricular assist device. For information, call Ramiah Subramanian at 301/443-8320
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.